Medicine · 13 Nov 2026
Risk-adapted active surveillance for prostate cancer: Can mpMRI, biomarkers, and genomic classifiers reduce biopsy burden without compromising safety?: A systematic review
Bilal Ahmadh-index 1, Saad Masood, Shabir Zarifh-index 1
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Background: Active surveillance is the preferred management strategy for men with low-risk and selected favorable intermediate-risk prostate cancer. However, conventional surveillance protocols rely heavily on repeated systematic biopsies, which impose procedural morbidity, patient burden, and limited precision in identifying true disease progression. Risk-adapted tools, including multi parametric magnetic resonance imaging (mpMRI), molecular biomarkers, and genomic classifiers, have emerged as potential strategies to optimize surveillance intensity while preserving oncologic safety. To systematically evaluate the evidence supporting risk-adapted AS strategies incorporating mpMRI, molecular biomarkers, and genomic classifiers, with a focus on reducing biopsy burden without compromising oncologic outcomes. Methods: A systematic review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed/MEDLINE, Embase, and Scopus were searched for peer-reviewed studies evaluating mpMRI, molecular biomarkers, or genomic classifiers within AS cohorts. Randomized controlled trials and prospective or retrospective cohort studies reporting surveillance-related outcomes were included. Primary outcomes included biopsy upgrading or reclassification, AS failure, and oncologic safety endpoints. Due to methodological heterogeneity, results were synthesized narratively. Results: Five publications met inclusion criteria, representing four unique studies one randomized controlled trial and three observational cohorts and 1215 participants. The 2 Active Surveillance Magnetic Resonance Imaging Study publications were treated as linked reports from the same trial. Baseline mpMRI with targeted and systematic biopsy was associated with lower subsequent AS failure and upgrading, but biopsy avoidance was not directly tested. An MRI-led cohort omitted routine protocol biopsies, although the absence of a concurrent comparator precluded conclusions about equivalent oncologic safety. The 4Kscore demonstrated potential for confirmatory-biopsy triage; a hypothetical deferral strategy could have avoided 27% of biopsies but would have missed 2 Grade Group 2 upgrades. The Decipher genomic classifier independently predicted biopsy upgrading, although biopsy reduction was not evaluated. Evidence establishing the long-term oncologic safety of biopsy reduction remained insufficient. Conclusion: Risk-adapted AS strategies incorporating mpMRI, molecular biomarkers, and genomic classifiers may improve risk stratification and support selective adjustment of biopsy intensity. However, current evidence does not establish the safety of routine biopsy omission or fully biopsy-free surveillance. Integration of these tools should remain individualized, with histologic reassessment when indicated and prospective validation of biopsy-deferral strategies.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Bilal Ahmad has the highest h-index among the authors (1).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (27)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 7 more references
A free account opens the rest of the citing papers and references on every paper’s page.